Ulipristal acetate 5 mg for uterine fibroids not to be used during ongoing review of liver injury risk

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Active substance
uliprista acetate 5mg
Therapeutic area (MeSH)
Leiomyoma
Procedure number
EMEA/H/A-31/1496
Regulatory outcome
Suspension
DHPC type
Interim measures
Referral name
Ulipristal acetate 5mg medicinal products
Dissemination date
23/03/2020

How useful was this page?

Add your rating